Hydrazone derivatives as kinase inhibitors
    1.
    发明授权
    Hydrazone derivatives as kinase inhibitors 有权
    腙衍生物作为激酶抑制剂

    公开(公告)号:US07893064B2

    公开(公告)日:2011-02-22

    申请号:US11871472

    申请日:2007-10-12

    IPC分类号: C07D403/12 A61K31/506

    CPC分类号: C07D403/12

    摘要: The present invention is directed to novel bicyclic pyrimidine compounds of Formula (I) or a form or composition thereof as inhibitors of ATP-protein kinase interactions, wherein substituents on each side of the iminomethyl double bond in Formula (I) may be in the E or Z configuration; and wherein R1, R2, R3 and R4 are as defined herein.

    摘要翻译: 本发明涉及式(I)的新型双环嘧啶化合物或其形式或组成作为ATP-蛋白激酶相互作用的抑制剂,其中式(I)中亚氨基甲基双键各侧的取代基可以在E 或Z配置; 并且其中R 1,R 2,R 3和R 4如本文所定义。

    HYDRAZONE DERIVATIVES AS KINASE INHIBITORS
    3.
    发明申请
    HYDRAZONE DERIVATIVES AS KINASE INHIBITORS 有权
    氢化衍生物作为激酶抑制剂

    公开(公告)号:US20080114004A1

    公开(公告)日:2008-05-15

    申请号:US11871472

    申请日:2007-10-12

    CPC分类号: C07D403/12

    摘要: The present invention is directed to novel bicyclic pyrimidine compounds of Formula (I) or a form or composition thereof as inhibitors of ATP-protein kinase interactions, wherein substituents on each side of the iminomethyl double bond in Formula (I) may be in the E or Z configuration; and wherein R1, R2, R3 and R4 are as defined herein.

    摘要翻译: 本发明涉及式(I)的新型双环嘧啶化合物或其形式或组成作为ATP-蛋白激酶相互作用的抑制剂,其中式(I)中亚氨基甲基双键各侧的取代基可以在E 或Z配置; 并且其中R 1,R 2,R 3和R 4都如本文所定义。

    Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
    9.
    发明授权
    Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders 有权
    用于治疗激酶障碍的嘧啶基取代的稠合吡咯基化合物

    公开(公告)号:US07855205B2

    公开(公告)日:2010-12-21

    申请号:US11260986

    申请日:2005-10-28

    IPC分类号: C07D403/04 A61K31/407

    CPC分类号: C07D471/04

    摘要: The present invention provides pyrimidinyl substituted fused-pyrrolyl compounds of Formula (I) and pharmaceutical compositions comprising the compounds and methods of synthesis and use thereof. The compounds are kinase inhibitors useful in treating or ameliorating a kinase mediated, angiogenesis-mediated or hyperproliferative disorder. The invention thus also provides a therapeutic or prophylactic method of use for the compounds and/or pharmaceutical compositions to treat such disorders.

    摘要翻译: 本发明提供式(I)的嘧啶基取代的稠合吡咯基化合物和包含该化合物的药物组合物及其合成和使用方法。 该化合物是可用于治疗或改善激酶介导的血管生成介导的或过度增殖性疾病的激酶抑制剂。 因此,本发明还提供了用于治疗这些疾病的化合物和/或药物组合物的治疗或预防方法。